Table 3 Univariate and multivariate analyses of adverse factors associated with OS and GFFS.
Outcome | No. of events/evaluable (5-year survival rate %) | Univariate | Multivariate | |
|---|---|---|---|---|
P value (log rank) | P value (COX) | Hazard ratio (95% confidence interval) | ||
OS | ||||
Interval from diagnosis to HSCT, days | 0.001* | |||
< = 75 | 0/18 (100.0%) | |||
> 75 | 8/17 (46.6%) | |||
Degree of HLA matching | 0.033*# | 0.006 | 8.2 (2.6–19.7) | |
< 7/10 | 5/12 (44.4%) | |||
> = 7/10 | 3/23 (86.1%) | |||
Donor age, years | 0.096 | |||
< 20 | 0/9 (100.0%) | |||
> = 20 | 8/25 (65.8%) | |||
Donor–patient sex match | 0.057# | 0.008 | 7.1 (2.4–16.5) | |
Sex match | 3/22 (81.4%) | |||
Sex mismatch | 5/13 (59.2%) | |||
EBV viremia after HSCT | 0.015* | |||
Yes | 2/3 (33.3%) | |||
No | 6/32 (77.7%) | |||
Liver events after HSCT | 0.035*# | 0.110 | ||
Yes | 6/14 (51.4%) | |||
No | 2/21 (90.2%) | |||
II–IV aGVHD after HSCT | < 0.001* | |||
Yes | 7/13 (35.2%) | |||
No | 0/21 (100.0%) | |||
III–IV aGVHD after HSCT | < 0.001* | |||
Yes | 3/4 (25.0%) | |||
No | 4/30 (83.4%) | |||
CD34+ cells in allografts, 106/kg | 0.014* | |||
< = 4.5 | 4/27 (81.8%) | |||
> 4.5 | 3/5 (40.0%) | |||
CD3+ CD4+ cells in allografts, 106/kg | 0.002* | |||
< = 125.0 | 2/23 (91.3%) | |||
> 125.0 | 4/6 (25.0%) | |||
CD3+ CD8+ cells in allografts, 106/kg | 0.075 | |||
< = 52.0 | 1/13 (92.3%) | |||
> 52.0 | 5/16 (49.2%) | |||
GFFS | ||||
Interval from diagnosis to HSCT, days | 0.036*# | 0.049* | 3.8 (1.0–14.6) | |
< = 75 | 3/18 (82.2%) | |||
> 75 | 8/17 (47.6%) | |||
Degree of HLA matching | 0.004*# | 0.019* | 4.4 (1.3–15.5) | |
< 7/10 | 7/12 (35.0%) | |||
> = 7/10 | 4/23 (81.0%) | |||
MNC in allografts, 108/kg | 0.028* | |||
< = 12.5 | 7/26 (70.2%) | |||
> 12.5 | 4/6 (33.3%) | |||
CD3+ cells in allografts, 106/kg | 0.044*# | 0.112 | ||
< = 115.0 | 1/9 (88.9%) | |||
> 115.0 | 10/20 (48.0%) | |||
